Psychiatry Medical News about Duloxetine treatment IBS

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Omega-3 fatty acids for bipolar disorder

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Duloxetine in the treatment of irritable bowel syndrome: an open-label pilot study
Human Psychopharmacology: Clinical and Experimental, 07/01/09

Brennan BP et al. - Open-label study, duloxetine appeared to be effective for many features of IBS, but its adverse effects, most notably constipation, limited its use. Since our study excluded individuals with concurrent major depression, it appears that duloxetine may benefit IBS independently of its antidepressant effects. These encouraging but preliminary open-label findings support further investigation of duloxetine treatment in placebo-controlled trials of IBS.

Methods

Open-label 12-week trial of duloxetine 60 mg daily in 15 patients with IBS without concurrent major depressive disorder.
The primary outcome measure was average abdominal pain.
Secondary measures included IBS symptoms, Clinical Global Impression-Severity, Hamilton Anxiety Rating Scale, IBS Quality-of-Life Scale, and Sheehan Disability Scale.
Analyzed changes using random regression and one-sample t-tests.

Results

Fourteen patients completed at least one post-baseline evaluation; eight completed the study.
Duloxetine was associated with significant improvement (p < 0.05) in pain, severity of illness, quality of life, loose stool, work and family disability, and anxiety.
However, duloxetine did not improve hard stool.
Found no evidence of serious duloxetine toxicity, seven participants withdrew over the course of the study because of adverse drug events.

<< Previous
A randomized double-blind trial of the effects of hormone therapy...

Next >>
Melatonin as a potential therapeutic agent in psychiatric illness